D. E. Shaw & Co., Inc. Apellis Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 251,069 shares of APLS stock, worth $5.98 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

251,069

Previous 38,100 558.97%

Holding current value

$5.98 Million

Previous $833,000 421.73%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$16.36 - $23.0 $4.11 Million - $5.77 Million	251,069 New	251,069 $4.35 Million
Q4 2024 Feb 14, 2025	BUY	$26.18 - $35.42 $523,600 - $708,400	20,000 New	20,000 $638,000
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $237,213 - $414,005	-6,387 Reduced 16.18%	33,086 $1.98 Million
Q3 2023 Nov 14, 2023	SELL	$23.65 - $89.22 $11.5 Million - $43.6 Million	-488,338 Reduced 92.52%	39,473 $1.5 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $8.81 Million - $10.7 Million	114,958 Added 27.84%	527,811 $48.1 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $18.6 Million - $26.8 Million	399,955 Added 3100.91%	412,853 $27.2 Million
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $7.98 Million - $11.3 Million	-184,466 Reduced 93.46%	12,898 $666,000
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $8.63 Million - $13.4 Million	192,794 Added 4218.69%	197,364 $13.5 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $998,232 - $1.69 Million	-28,464 Reduced 86.17%	4,570 $207,000
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $172,193 - $262,806	-4,856 Reduced 12.82%	33,034 $1.68 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $1.16 Million - $1.85 Million	-37,632 Reduced 49.83%	37,890 $1.79 Million
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $5.32 Million - $11.8 Million	-169,507 Reduced 69.18%	75,522 $2.49 Million
Q2 2021 Aug 16, 2021	SELL	$40.9 - $64.9 $3.75 Million - $5.95 Million	-91,614 Reduced 27.21%	245,029 $15.5 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $3.16 Million - $4.44 Million	-77,419 Reduced 18.7%	336,643 $14.4 Million
Q4 2020 Feb 16, 2021	BUY	$30.79 - $57.2 $868,154 - $1.61 Million	28,196 Added 7.31%	414,062 $23.7 Million
Q3 2020 Nov 16, 2020	SELL	$25.89 - $33.65 $3.78 Million - $4.91 Million	-145,895 Reduced 27.44%	385,866 $11.6 Million
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $4.02 Million - $6.24 Million	162,028 Added 43.82%	531,761 $17.4 Million
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $3.96 Million - $9.81 Million	221,326 Added 149.13%	369,733 $9.91 Million
Q4 2019 Feb 14, 2020	BUY	$22.1 - $30.8 $3.04 Million - $4.23 Million	137,342 Added 1241.23%	148,407 $4.54 Million
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $266,555 - $356,071	11,065 New	11,065 $267,000

Others Institutions Holding APLS

# of Institutions

295

Shares Held

132M

Call Options Held

2.97M

Put Options Held

623K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.61B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account